US3449314A - Preparation of anti-rh globulin from human plasma - Google Patents

Preparation of anti-rh globulin from human plasma Download PDF

Info

Publication number
US3449314A
US3449314A US555175A US3449314DA US3449314A US 3449314 A US3449314 A US 3449314A US 555175 A US555175 A US 555175A US 3449314D A US3449314D A US 3449314DA US 3449314 A US3449314 A US 3449314A
Authority
US
United States
Prior art keywords
precipitate
supernatant
methanol
iii
globulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US555175A
Inventor
William Pollack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Application granted granted Critical
Publication of US3449314A publication Critical patent/US3449314A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions

Definitions

  • the present invention relates to the production of gamma globulin and more particularly to a method of production of anti-Rh globulin.
  • Erythroblastosis fetalis is a herolytic disease which may cause brain damage, heart damage or death in the newborn child. This disease is caused by placenta-passing anti-bodies against fetal erythrocytes from a pregnant woman to her fetus. The disease is common in the children of parents whose blood have differing Rhfactors, as for example, the children of an Rh-uegative mother and an Rh-positive father.
  • red blood cells from the fetus may pass into her circulation. If the woman is Rh-negative and her husband is Rh-positive, the fetal red blood cells are usually Rhpositive. Antibodies to the Rh-positive red blood cell-s only rarely develop in the mothers circulation during the rst pregnancy and the first child is unaffected. Subsequent to the pregnancy, the ⁇ Rh-positive fetal erythrocytes remaining in the maternal circulation may immunize the mother so that she has about a 9 to 20% chance of producing Rh-antibodies.
  • Rh-positive antibodies in the mothers ⁇ circulation pass through the placenta into the circulation of the fetus and destroy the fetal red blood cells causing erythroblastosis fetalis. Since about 15 percent of the population are Rh-negative, the disease is not uncommon.
  • U.S. Patent No. 2,390,074 discloses a method of fractionating blood by which gamma globulins are prepared.
  • the gamma globulins prepared by the Cohn method contain 19 S globulin, plasminogen and lipids. While this gamma globulin is eminently suitable for prophylaxis against diseases such as measles and tetanus, the presence of the 19 S globulin, plasminogen and lipids are unnecessary contaminants and may decrease its effectiveness in preventing immunization to the Rhfactor on the fetal erythrocytes.
  • the anti-Rh globulin of the present invention is prepared from human plasma which contains albumin, plasminogen, alpha, beta and gamma globulins and various lipids. Specifically, the anti-Rh globulin of the invention is a gamma G globulin.
  • the fractionation of human plasma toy obtain anti-Rh globulin is carried out according to the accompanying flow sheet.
  • the ability to fractionate human plasma is dependent upon the solubility of the various components of the plasma.
  • the separation of the fraction and the ultimate removal of those components which are undesirable in the anti-Rh globulin are determined by the critical control of pH, temperature, concentration of the precipitant and the ionic strength of the system.
  • organic solvents of low dielectric constant such as acetone and alcohols, precipitate proteins and have been used in the fractionation of plasma.
  • the organic solvent utilized in the method of this invention is methanol.
  • the ability to maintain the critical ionic vStrengths at the various stages of the fractionation is dependent upon the use of methanol.
  • precipitation is carried out :at low temperatures. Since protein solubility is temperature dependent, the temperature chosen for each step of the fractionation must be the lowest possible which permits the desired separation in order to prevent denaturation.
  • the fractionation proceeds from whole human plasma.
  • the plasma is cooled to about 1 C. and is then centrifuged to separate a cold insoluble precipitate from a supernatant.
  • the supernatant is further fractionated to yield Precipitate I and Supernatant I.
  • Precipitate I which consists principally of fibrinogen is discarded.
  • Supernatant I is further fractionated to yield Supernatant IIA-III and Precipitate lI-l-III.
  • Supernatant ⁇ II-l-[EIL which is discarded, contains alpha and beta globulin and lipids.
  • Precipitate II-l-III consists principally of beta and gamma globulins and isoagglutinins, but also contains prothrombin, plasminogen, cholesterol and other lipids.
  • Precipitate lI-l-III upon further fractionation yields Supernatant II-l-III W and Precipitate II-i-III W.
  • the beta globulin, cholesterol and other lipids are largely removed in Supernatant II-i-III W which is discarded.
  • Precipitate II-l-III W consists principally of gamma globulins, isoagglutinins, plasminogen and prothrombin and some beta globulin, cholesterol and other lipids.
  • Precipitate II-l-III W Upon further fractionation, Precipitate II-l-III W yields Supernatant IIl-l-Precipitate III.
  • Precipitate III which is discarded, contains isoagglutinins, plasminogen and prothrombin, Supernatant III consists principally of gamma globulins and minor amouts of fibrinogen and lipids.
  • the final step of the fractionation yields Precipitate II which is essentially pure gamma G globulin almost completely free of 19 S globulin, plasminogen and lipids.
  • Precipitate II prepared by the process of the invention is an anti-Rh gamma globulin.
  • Human blood plasma is cooled to 1il C.
  • the plasma is centrifuged in a Sha-rples Super-Centrifuge with a 3-wing in bowl, at lil C. feeding at the ra-te of 1000i50 ml. per minute.
  • the cold insoluble precipitate is discarded.
  • the pH of the supernatant is adjusted to 7.2i0.2.
  • the methanol content of the batch is brought to 10.7i0.l% (V./v.) by the addition of 177 ml. of 71% (v./v.) methanol per liter of plasma.
  • the solution is stirred slowly at -5i0.5 C. for one hour and is maintained at -5i0.5 C. overnight.
  • the solution is centrifuged in a Sharples Super-Centrifuge with a 3-wing in bowl at -5i0.5 C., feeding at the rate of 1000il00 ml. per minute.
  • Supernatant I is collected in a bowl equipped with cooling device.
  • the solution is centrifuged in a Sharples Super-Centrifuge with a 3-wing in bowl at -5l 0.5 C., at a rate of 1000 mLilOO rnl. per minute.
  • Precipitate II-l-III is removed from the bowl, weighed, and is stored at a temperature of 20 C.
  • Precipitate II-l-III is suspended in 2 volumes (2 times original weight of Precipitate II-i-III) of 0 C. water in equilibrium with ice by cutting up the paste with a stainless steel spatula in a stainless steel pot and stirring until the suspension is uniform. 3 volumes (3 times original weight of Precipitate II-i-III) of 0.0187 M disodium phosphate solution is added to the suspension with stirring. 20 volumes (20 times original Weight of Precipitate II-i-III) of Water at 0 C. is added and the stirring at 0 C. is continued for 30-60 minutes. The pH is 7.2i0.2.
  • the solution is brought to a temperature of 5 C. and is centrifuged in the Sharples Super-Centrifuge with a 3-wing in bowl at a temperature of 5.5 10.5 C. at a rate Of 500i50 ml. per minute.
  • Precipitate II-i-III W is removed from the bowl and is weighed.
  • Precipitate II-l-III W is suspended in 2 volumes (2 times weight of Precipitate II-l-III W) of ice water. To the suspension is added 2 volumes (2 times weight of Precipitate II-l-III W) of 0.175 M sodium acetate. A further 1 volume (1 times weight of Precipitate II-i-III W) of ice water containing 0.216 ml. of acetate buffer for each gram of Precipitate II-l-III W paste.
  • the acetate buffer is prepared by diluting 40 ml. of 10 N acetic acid and 20 ml. of 4 N sodium acetate to 100 ml. with distilled water. The pH of the solution is 5.2i0.2. The solution is stirred slowly for one hour.
  • the solution is centrifuged in a Sharples Super-Centrifuge with a 3-wing in bowl, at a temperature of -6i0.5 C., and at a flow rate of 500i50 ml. per minute.
  • the volume of Supernatant III is measured. Precipitate III is discarded.
  • Supernatant III is treated with 0.4% w./v. Celite 512 and is stirred for 20 minutes. The mixture is ltered through an Eitel lter press containing D-S pads.
  • An acetate buffer of pH 5.2 is made up as follows: 25 ml. 4 N sodium acetate and 3 ml. 10 N acetic acid made up to 100 ml. with distilled water. The acetate buer is diluted 100 times with 22.7% methanol. This solution has an ionic strength of 0.01 gi./liter.
  • A-n Eitel filter press is precoated with the acetate buffer plus Celite 512 (0.5 gm./square inch of pad surface) using 40 ml. of acetatemethanol buffer/square inch of pad surface.
  • Supernatant III is filtered and to the filtrate is added 50 millimoles (2.923 grams) of sodium chloride and 7.65 ml. of 1 M sodium bicarbonate per liter of filtered Supernatant III.
  • the pH of the ltrate is 7.21 0.2.
  • the solution is centrifuged in a Sharples Super-Centrifuge with 3-wing in bowl, at a temperature of -6i0.5 C. and at a ow rate of 500i50 ml. per minute. The supernatant is discarded.
  • Precipitate II is removed, suspended in 4 volumes of ice water and freeze-dried. The freeze-dried powder is weighed and is stored below at a temperature of 5 C.
  • Precipitate II as prepared 'by this example is 99% gamma G globulin free from plasminogen, lipids and 19 S globulins, having an electrophoretic mobility not greater than 1.1)(10-5 cm.2/volt/sec. in veronal buffer, pH 8.6, ionic strength 0.1 gi./liter. Precipitate II also contains about 0.99% sodium chloride.
  • a method of preparing an anti-Rh gamma globulin from human plasma which comprises the steps of:

Description

June 10, 1969 w. PoLLAcK 3,449,314 PREPARATION OF ANT-.[*Rh GLOBULN FROM HUMAN PLASMA Filed'dune 3, 1966 United States Patent Office 3,449,314 Patented June 10, 1969 3,449,314 PREPARATION F ANTI-Rh GLBULIN FROM HUMAN PLASMA William Pollack, Belle Mead, NJ., assignor to Ortho Pharmaceutical Corporation, a corporation of New Jersey Filed .lune 3, 1966, Ser. No. 555,175 Int. Cl. A23j 1/06; C07g 7/00; A61k 23/ 00 U.S. Cl. 260--112 2 Claims The present invention relates to the production of gamma globulin and more particularly to a method of production of anti-Rh globulin.
Erythroblastosis fetalis is a herolytic disease which may cause brain damage, heart damage or death in the newborn child. This disease is caused by placenta-passing anti-bodies against fetal erythrocytes from a pregnant woman to her fetus. The disease is common in the children of parents whose blood have differing Rhfactors, as for example, the children of an Rh-uegative mother and an Rh-positive father.
When a woman whose Rh-factor differs from that of her husband becomes pregnant for the first time, red blood cells from the fetus may pass into her circulation. If the woman is Rh-negative and her husband is Rh-positive, the fetal red blood cells are usually Rhpositive. Antibodies to the Rh-positive red blood cell-s only rarely develop in the mothers circulation during the rst pregnancy and the first child is unaffected. Subsequent to the pregnancy, the `Rh-positive fetal erythrocytes remaining in the maternal circulation may immunize the mother so that she has about a 9 to 20% chance of producing Rh-antibodies. During subsequent pregnancies, the Rh-positive antibodies in the mothers `circulation pass through the placenta into the circulation of the fetus and destroy the fetal red blood cells causing erythroblastosis fetalis. Since about 15 percent of the population are Rh-negative, the disease is not uncommon.
Freda, Gorman and Pollack have reported that the intramuscular injection of anti-Rh gamma globulin into an Rh-negative mother within 72 hours of partruition will prevent the production in her circulation of antibodies which may cause erythroblastosis fetalis in the fetus of her next pregnancy (Science, Feb. 18, 1966, vol. 151, No. 3712, pages 823-830).
Cohn, U.S. Patent No. 2,390,074 discloses a method of fractionating blood by which gamma globulins are prepared. The gamma globulins prepared by the Cohn method contain 19 S globulin, plasminogen and lipids. While this gamma globulin is eminently suitable for prophylaxis against diseases such as measles and tetanus, the presence of the 19 S globulin, plasminogen and lipids are unnecessary contaminants and may decrease its effectiveness in preventing immunization to the Rhfactor on the fetal erythrocytes.
The anti-Rh globulin of the present invention is prepared from human plasma which contains albumin, plasminogen, alpha, beta and gamma globulins and various lipids. Specifically, the anti-Rh globulin of the invention is a gamma G globulin.
The fractionation of human plasma toy obtain anti-Rh globulin is carried out according to the accompanying flow sheet. The ability to fractionate human plasma is dependent upon the solubility of the various components of the plasma. At each stage of the fractionation, the separation of the fraction and the ultimate removal of those components which are undesirable in the anti-Rh globulin are determined by the critical control of pH, temperature, concentration of the precipitant and the ionic strength of the system.
Various organic solvents of low dielectric constant such as acetone and alcohols, precipitate proteins and have been used in the fractionation of plasma. The organic solvent utilized in the method of this invention is methanol. The ability to maintain the critical ionic vStrengths at the various stages of the fractionation is dependent upon the use of methanol.
In order to prevent denaturation of the proteins during fractionation, precipitation is carried out :at low temperatures. Since protein solubility is temperature dependent, the temperature chosen for each step of the fractionation must be the lowest possible which permits the desired separation in order to prevent denaturation.
Referring to the ilowsheet, the fractionation proceeds from whole human plasma. The plasma is cooled to about 1 C. and is then centrifuged to separate a cold insoluble precipitate from a supernatant. The supernatant is further fractionated to yield Precipitate I and Supernatant I. Precipitate I which consists principally of fibrinogen is discarded. Supernatant I is further fractionated to yield Supernatant IIA-III and Precipitate lI-l-III. Supernatant `II-l-[EIL which is discarded, contains alpha and beta globulin and lipids. Precipitate II-l-III consists principally of beta and gamma globulins and isoagglutinins, but also contains prothrombin, plasminogen, cholesterol and other lipids. Precipitate lI-l-III, upon further fractionation yields Supernatant II-l-III W and Precipitate II-i-III W. The beta globulin, cholesterol and other lipids are largely removed in Supernatant II-i-III W which is discarded. Precipitate II-l-III W consists principally of gamma globulins, isoagglutinins, plasminogen and prothrombin and some beta globulin, cholesterol and other lipids. Upon further fractionation, Precipitate II-l-III W yields Supernatant IIl-l-Precipitate III. Precipitate III, which is discarded, contains isoagglutinins, plasminogen and prothrombin, Supernatant III consists principally of gamma globulins and minor amouts of fibrinogen and lipids. The final step of the fractionation yields Precipitate II which is essentially pure gamma G globulin almost completely free of 19 S globulin, plasminogen and lipids. Precipitate II prepared by the process of the invention is an anti-Rh gamma globulin.
The invention may be more fully understood with reference to the following example.
Human blood plasma is cooled to 1il C. The plasma is centrifuged in a Sha-rples Super-Centrifuge with a 3-wing in bowl, at lil C. feeding at the ra-te of 1000i50 ml. per minute. The cold insoluble precipitate is discarded. The pH of the supernatant is adjusted to 7.2i0.2. The methanol content of the batch is brought to 10.7i0.l% (V./v.) by the addition of 177 ml. of 71% (v./v.) methanol per liter of plasma. The solution is stirred slowly at -5i0.5 C. for one hour and is maintained at -5i0.5 C. overnight. The solution is centrifuged in a Sharples Super-Centrifuge with a 3-wing in bowl at -5i0.5 C., feeding at the rate of 1000il00 ml. per minute. Supernatant I is collected in a bowl equipped with cooling device.
To each liter of Supernatant I there is added, with cooling, 601 ml. of 71% (v./v.) methanol, 0.88 ml. of 10 N acetic acid, and 0.44 ml. of 4 N sodium acetate. This brings the methanol concentration to 33.3%, the ionic strength to 0.086 gi./liter and the pH to 6.9. The solution is brought to a temperature of 5i0.5 C. and is stirred slowly for two hours. The solution is then allowed to stand at -5.5i0.5 C. for 16 hours.
The solution is centrifuged in a Sharples Super-Centrifuge with a 3-wing in bowl at -5l 0.5 C., at a rate of 1000 mLilOO rnl. per minute. Precipitate II-l-III is removed from the bowl, weighed, and is stored at a temperature of 20 C.
Maintaining a temperature of C., Precipitate II-l-III is suspended in 2 volumes (2 times original weight of Precipitate II-i-III) of 0 C. water in equilibrium with ice by cutting up the paste with a stainless steel spatula in a stainless steel pot and stirring until the suspension is uniform. 3 volumes (3 times original weight of Precipitate II-i-III) of 0.0187 M disodium phosphate solution is added to the suspension with stirring. 20 volumes (20 times original Weight of Precipitate II-i-III) of Water at 0 C. is added and the stirring at 0 C. is continued for 30-60 minutes. The pH is 7.2i0.2. To obtain a methanol percentage of 26.7i0.2%, 15 volumes (15 times the original Weight of Precipitate 114-111) of 71% (v./v.) methanol at C. is added. The ionic strength of the solution is 0.0052i0-0005 gi./liter.
The solution is brought to a temperature of 5 C. and is centrifuged in the Sharples Super-Centrifuge with a 3-wing in bowl at a temperature of 5.5 10.5 C. at a rate Of 500i50 ml. per minute. Precipitate II-i-III W is removed from the bowl and is weighed.
Precipitate II-l-III W is suspended in 2 volumes (2 times weight of Precipitate II-l-III W) of ice water. To the suspension is added 2 volumes (2 times weight of Precipitate II-l-III W) of 0.175 M sodium acetate. A further 1 volume (1 times weight of Precipitate II-i-III W) of ice water containing 0.216 ml. of acetate buffer for each gram of Precipitate II-l-III W paste. The acetate buffer is prepared by diluting 40 ml. of 10 N acetic acid and 20 ml. of 4 N sodium acetate to 100 ml. with distilled water. The pH of the solution is 5.2i0.2. The solution is stirred slowly for one hour. There is then added 13.5 volumes (13.5 times the original weight of Precipitate II-l-III W) of ice water and 8.66 volumes (8.66 times the original weight of Precipitate II|III W) of 71% (v /v.) methanol while maintaining the temperature atv 6i0.5 C. The solution is stirred slowly for one hour and is allowed to stand overnight. The solution contains 22.7% methanol and has a pH of 5.2 and an ionic strength of 0.015 gi./liter.
The solution is centrifuged in a Sharples Super-Centrifuge with a 3-wing in bowl, at a temperature of -6i0.5 C., and at a flow rate of 500i50 ml. per minute. The volume of Supernatant III is measured. Precipitate III is discarded.
Supernatant III is treated with 0.4% w./v. Celite 512 and is stirred for 20 minutes. The mixture is ltered through an Eitel lter press containing D-S pads.
An acetate buffer of pH 5.2 is made up as follows: 25 ml. 4 N sodium acetate and 3 ml. 10 N acetic acid made up to 100 ml. with distilled water. The acetate buer is diluted 100 times with 22.7% methanol. This solution has an ionic strength of 0.01 gi./liter. A-n Eitel filter press is precoated with the acetate buffer plus Celite 512 (0.5 gm./square inch of pad surface) using 40 ml. of acetatemethanol buffer/square inch of pad surface. Supernatant III is filtered and to the filtrate is added 50 millimoles (2.923 grams) of sodium chloride and 7.65 ml. of 1 M sodium bicarbonate per liter of filtered Supernatant III. The pH of the ltrate is 7.21 0.2.
To the ltrate is added 160 volumes of 100% methanol at a temperature below 5 C. The mixture is stirred slowly for 1 hour at a temperature of 6.5 i0.5 C. The mixture is permitted to stand overnight.
The solution is centrifuged in a Sharples Super-Centrifuge with 3-wing in bowl, at a temperature of -6i0.5 C. and at a ow rate of 500i50 ml. per minute. The supernatant is discarded.
Precipitate II is removed, suspended in 4 volumes of ice water and freeze-dried. The freeze-dried powder is weighed and is stored below at a temperature of 5 C.
Precipitate II as prepared 'by this example is 99% gamma G globulin free from plasminogen, lipids and 19 S globulins, having an electrophoretic mobility not greater than 1.1)(10-5 cm.2/volt/sec. in veronal buffer, pH 8.6, ionic strength 0.1 gi./liter. Precipitate II also contains about 0.99% sodium chloride.
What is claimed is:
1. A method of preparing an anti-Rh gamma globulin from human plasma which comprises the steps of:
(a) cooling human plasma to about 1 C. and separating from said plasma a rst supernatant and a first precipitate;
(b) adding methanol to said rst supernatant and adjusting the temperature to about 2 C., the amount of said methanol being between 10.5% and 10.9%, the pH being between 7 and 7.4 and the ionic strength being 0.136 gi./liter and separating from the resulting liquid system a second precipitate and a second supernatant;
(c) adding methanol to said second supernatant and adjusting the temperature to about 5 C., the amount of said methanol being between 33.25% and 33.35%, the pH being between 6.7 and 7.1 a-nd the ionic strength being between 0.081 and 0.091 gi./liter and separating from the resulting liquid system a third precipitate and a third supernatant;
(d) adding methanol to said third precipitate and adjusting the temperature to about 5 C., the amount of said methanol being between 26.5% and 26.9%, the pH being between 7.0 and 7.4 and the ionic strength being between 0.0047 and 0.0057 gi./liter and separating from the resulting liquid system a fourth precipitate and a fourth supernatant;
(e) adding methanol to said fourth precipitate and adjusting the temperature to about 6 C., the amount of said methanol being between 22.5% and 22.9%, the pH being between 5.0 and 5.4 and the ionic strength being between 0.008 and 0.018 gi./liter and separating from the resulting liquid system a fth precipitate and a fifth supernatant;
(f) adding methanol to said fifth supernatant and adjusting the temperature to about 6.5 C., the amount of said methanol being between 33.0% and 33.4%, the pH being between 7.0 and 7.4 and the ionic strength being between 0.055 and 0.065 gi./1iter and separating said resulting liquid system into a sixth precipitate and a sixth supernatant.
2. A method according to claim 1, wherein said sixth precipitate is freeze-dried.
References Cited Journal of Physiology, 1934, vol. VIII, pp. 97-109, Lui. Journal of Biological Chemistry, vol. 158, pp. 299-301.
WILLIAM H. SHORT, Primary Examiner.
HOWARD SHAIN, Assistant Examiner.
U.S. Cl. X.R. 424-11, 101

Claims (1)

1. A METHOD OF PREPARING AN ANTI-RH GAMMA GLOBULIN FROM HUMAN PLASMA WHICH CONPRISES THE STEPS OF: (A) COOLING HUMAN PLASMA TO ABOUT 1*C. AND SEPARATING FROM SAID PLASMA A FIRST SUPERNATANT AND A FIRST PRECIPITATE; (B) ADDING METHANOL TO SAID FIRST SUPERNATANT AND ADJUSTING THE TEMPERATURE TO ABOUT-2*C., THE AMOUNT OF SAID METHANOL BEING BETWEEN 10.5% AND 10.9%, THE PH BEING BETWEEN 7 AND 7.4 AND THE IONIC STRENGTH BEING 0.136 GI./LITER AND SEPARATING FROM THE RESULTING LIQUID SYSTEM A SECOND PRECIPITATE AND A SECOND SUPERNANT; (C) ADDING METHANOL TO SAID SECOND SUPERNATANT AND ADJUSTING THE TEMPERATURE TO ABOUT -5*C., THE AMOUNT OF SAID METHANOL BEING BETWEEN 33.25% AND 33.35%, THE PH BEING BETWEEN 6.7 AND 7.1 AND THE IONIC STRENGTH BEING BETWEEN 0.081 AND 0.091 GI./LITER AND SEPARATING FROM THE RESULTING LIQUID SYSTEM A THIRD PRECIPITATE AND A THIRD SUPERNATANT; (D) ADDING METHANOL TO SAID THIRD PRECIPITATE AND ADJUSTING THE TEMPERATURE TO ABOUT-5*C., THE AMOUNT OF SAID METHANOL BEING BETWEEN 26.5% AND 26.9%, THE PH BEING BETWEEN 7.0 AND 7.4 AND THE IONIC STRENGTH BEING BETWEEN 0.0047 AND 0.0057 GI./LITER AND SEPARATING FROM THE RESULTING LIQUID SYSTEM A FOURTH PRECIPITATE AND A FOURTH SUPERNATANT; (E) ADDING METHANOL TO SAID FOURTH PRECIPITATE AND ADJUSTING THE TEMPERATURE TO ABOUT-6*C., THE AMOUNT OF SAID METHANOL BEING BETWEEN 22.5% AND 22.9%, THE PH BEING BETWEEN 5.0 AND 5.4 AND THE IONIC STRENGTH BEING BETWEEN 0.008 AND 0.018 GI./LITER AND SEPARATING FROM THE RESULTING LIQUID SYSTEM A FIFTH PRECIPITATE AND A FIFTH SUPERNATANT; (F) ADDING METHANOL TO SAID FIFTH SUPERNATANT AND ADJUSTING THE TEMPERATURE OF ABOUT-6.5*C., THE AMOUNT OF SAID METHANOL BEING BETWEEN 33.0% AND 33.4%, THE PH BEING BETWEEN 7.0 AND 7.4 AND THE IONIC STRENGTH BEING BETWEEN 0.055 AND 0.065 GI./LITER AND SEPARATING SAID RESULTING LIQUID SYSTEM INTO A SIXTH PRECIPITATE AND A SIXTH SUPERNATANT.
US555175A 1966-06-03 1966-06-03 Preparation of anti-rh globulin from human plasma Expired - Lifetime US3449314A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55517566A 1966-06-03 1966-06-03

Publications (1)

Publication Number Publication Date
US3449314A true US3449314A (en) 1969-06-10

Family

ID=24216259

Family Applications (1)

Application Number Title Priority Date Filing Date
US555175A Expired - Lifetime US3449314A (en) 1966-06-03 1966-06-03 Preparation of anti-rh globulin from human plasma

Country Status (14)

Country Link
US (1) US3449314A (en)
BE (1) BE699251A (en)
CH (1) CH543886A (en)
CS (1) CS154570B2 (en)
DE (1) DE1617718A1 (en)
DK (1) DK114996B (en)
ES (1) ES341266A1 (en)
FI (1) FI47374C (en)
GB (1) GB1163493A (en)
GR (1) GR32294B (en)
IL (1) IL28058A (en)
NL (1) NL6707646A (en)
NO (1) NO122991B (en)
SE (1) SE331886C (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US4141887A (en) * 1976-05-31 1979-02-27 Arnold Seufert Process and apparatus for the production of sterile filtered blood clotting factors
WO1999019343A1 (en) * 1997-10-14 1999-04-22 Ortho Diagnostic Systems, Inc. Viral clearance process
US20040110931A1 (en) * 2001-04-02 2004-06-10 Holten Robert Van Prion and viral clearance process
US20060110399A1 (en) * 2004-11-18 2006-05-25 Van Holten Robert W Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin
US7201901B2 (en) 2002-05-23 2007-04-10 Ortho-Clinical Diagnostics, Inc. Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
US2761809A (en) * 1954-07-22 1956-09-04 Ortho Pharma Corp Preparation of blood fraction for use in rh testing procedures
US2761808A (en) * 1952-09-06 1956-09-04 Ortho Pharma Corp Plasma fractionation process
US2761811A (en) * 1954-07-22 1956-09-04 Ortho Pharma Corp Preparation of blood fraction for use in rh testing procedures
US2761810A (en) * 1954-07-22 1956-09-04 Ortho Pharma Corp Preparation of blood fraction for use in rh testing procedures
US2770616A (en) * 1951-01-29 1956-11-13 Protein Foundation Inc Fractionation of proteinaceous materials in blood plasma and liver tissue
US2790790A (en) * 1954-11-10 1957-04-30 Swift & Co Protein fractionation
US3361732A (en) * 1964-07-28 1968-01-02 Dow Chemical Co Method for concentration of blood protein solutions employing methanol and flash evaporation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
US2770616A (en) * 1951-01-29 1956-11-13 Protein Foundation Inc Fractionation of proteinaceous materials in blood plasma and liver tissue
US2761808A (en) * 1952-09-06 1956-09-04 Ortho Pharma Corp Plasma fractionation process
US2761809A (en) * 1954-07-22 1956-09-04 Ortho Pharma Corp Preparation of blood fraction for use in rh testing procedures
US2761811A (en) * 1954-07-22 1956-09-04 Ortho Pharma Corp Preparation of blood fraction for use in rh testing procedures
US2761810A (en) * 1954-07-22 1956-09-04 Ortho Pharma Corp Preparation of blood fraction for use in rh testing procedures
US2790790A (en) * 1954-11-10 1957-04-30 Swift & Co Protein fractionation
US3361732A (en) * 1964-07-28 1968-01-02 Dow Chemical Co Method for concentration of blood protein solutions employing methanol and flash evaporation

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US4141887A (en) * 1976-05-31 1979-02-27 Arnold Seufert Process and apparatus for the production of sterile filtered blood clotting factors
WO1999019343A1 (en) * 1997-10-14 1999-04-22 Ortho Diagnostic Systems, Inc. Viral clearance process
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US20040110931A1 (en) * 2001-04-02 2004-06-10 Holten Robert Van Prion and viral clearance process
US7201901B2 (en) 2002-05-23 2007-04-10 Ortho-Clinical Diagnostics, Inc. Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration
US20070148685A1 (en) * 2002-05-23 2007-06-28 Van Holten Robert W Capture, Concentration And Quantitation Of Abnormal Prion Protein From Biological Fluids Using Depth Filtration
US20060110399A1 (en) * 2004-11-18 2006-05-25 Van Holten Robert W Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin
US7655233B2 (en) 2004-11-18 2010-02-02 Ortho-Clinical Diagnostics, Inc. Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin
US20100129893A1 (en) * 2004-11-18 2010-05-27 Van Holten Robert W Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin

Also Published As

Publication number Publication date
DK114996B (en) 1969-08-25
GB1163493A (en) 1969-09-04
SE331886B (en) 1971-01-18
FI47374C (en) 1973-11-12
CH543886A (en) 1973-11-15
SE331886C (en) 1974-01-17
GR32294B (en) 1967-06-08
ES341266A1 (en) 1968-06-16
NL6707646A (en) 1967-12-04
BE699251A (en) 1967-11-30
IL28058A (en) 1971-08-25
DE1617718A1 (en) 1971-07-15
CS154570B2 (en) 1974-04-30
FI47374B (en) 1973-07-31
NO122991B (en) 1971-09-13

Similar Documents

Publication Publication Date Title
Curzon et al. The purification of human caeruloplasmin
NO168449B (en) MEASURING TRANSFORMER IN A HIGH VOLTAGE SWITCH
Tchernia et al. Deficiency of skeletal membrane protein band 4.1 in homozygous hereditary elliptocytosis. Implications for erythrocyte membrane stability.
Vonderheid et al. Neonatal lupus erythematosus: report of four cases with review of the literature
EVANS et al. The serology of autoimmune hemolytic disease: observations on forty-one patients
US3449314A (en) Preparation of anti-rh globulin from human plasma
Alpert et al. Immunosuppressive Characteristics of Human AFP: Effect on Tests of Cell Mediated Immunity and Induction of Humam Suppressor Cells
US4088748A (en) Hepatitis B surface antigen
US2710294A (en) Blood fractionation
US2710293A (en) Blood fractionation
US2793203A (en) Process of preparing stable, highly purified gamma globulin preparations
US4558035A (en) Material for use in the treatment of spontaneous abortions
Sabolović et al. Separation and characterization of cell subpopulations in the thymus
US3497492A (en) Preparation of placental albumin
Bastian et al. Maternal isoimmunisation resulting in combined immunodeficiency and fatal graft-versus-host disease in an infant
US2543215A (en) Process of preparing antibody-rich globulin fractions
Nagata et al. [58] The isolation and purification of wheat germ and other agglutinins
US2852431A (en) Process for the extraction and purification of relaxin using trichloracetic acid
US3382227A (en) Blood protein fractionation employing 2-ethoxy-6, 9-diamino-acridine-lactate
Morse The effect of human chorionic gonadotropin and placental lactogen on lymphocyte transformation in vitro
DE1617718C (en) Process for the production of anti-Rh-gamma-globulin
US4452893A (en) Cell growth medium supplement
Taylor et al. An improved procedure for the preparation of human serum albumin from placental extracts
Ness et al. Plasma fractionation in the United States: a review for clinicians
Cruchaud et al. Agammaglobulinemia in one of two identical twins